Literature DB >> 25054005

Rat injury model of docetaxel extravasation.

Jing-Jing Zhu1, Jian-Fei Fu2, Jiao Yang3, Bing Hu4, Hui Zhang5, Jian-Hua Yu2.   

Abstract

Docetaxel is a novel type of chemotherapy drug that actively treats a number of malignant tumors. The aim of the present study was to explore the severity and natural course of tissue damage induced by docetaxel extravasation and to confirm the vesicant potential of docetaxel. Rats were selected for the establishment of the ulcer model. Different volumes and concentrations were explored to induce the skin ulcer and to confirm the optimum rational injection model. The natural course of tissue injury and pathological changes produced by docetaxel extravasation were observed by comparing to vinorelbine extravasation. A 0.4 ml volume and a 6 mg/ml concentration were the optimum rational injection model for the induction of the skin ulcer. The docetaxel extravasation induced local tissue necrosis, followed by granuloma formation and hyperpigmentation or scar formation. The severity of the injury depended on the concentration of the extravasation used in the rat model. The injury occurred on the first day following extravasation and lasted 4-6 weeks. The damage from docetaxel was weaker than vinorelbine in association with the depth and extension of necrosis. In conclusion, docetaxel extravasation can induce tissue necrosis. However, the severity of necrosis was weaker than that of vinorelbine. Docetaxel has superficial vesicant properties.

Entities:  

Keywords:  docetaxel; extravasation; pathology; skin toxicity

Year:  2014        PMID: 25054005      PMCID: PMC4106538          DOI: 10.3892/br.2014.292

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  20 in total

1.  Docetaxel recall phenomenon at the site of previous drug extravasation.

Authors:  Blanca Díaz Ley; Guillermo Guhl Millán; Javier Sanchez Perez; Javier Fraga; Amaro García Díez
Journal:  Arch Dermatol       Date:  2010-10

2.  Extravasation of docetaxel: a red hand syndrome.

Authors:  Ramón Barceló; Ainhoa Viteri; Alberto Muñoz; Sergio Carrera; Itziar Rubio; Guillermo López-Vivanco
Journal:  Arch Dermatol       Date:  2005-10

3.  Eccrine squamous syringometaplasia secondary to cutaneous extravasation of docetaxel: report of three cases.

Authors:  Elena Gallo; Mar Llamas-Velasco; Raquel Navarro; Javier Fraga; Amaro García-Diez
Journal:  J Cutan Pathol       Date:  2012-11-21       Impact factor: 1.587

4.  Docetaxel extravasation.

Authors:  P Berghammer; R Pöhnl; M Baur; C Dittrich
Journal:  Support Care Cancer       Date:  2001-03       Impact factor: 3.603

5.  The First Description of Docetaxel-Induced Recall Inflammatory Skin Reaction After Previous Drug Extravasation.

Authors:  Frauke Kramer; Cordula Schippert; Franziska Rinnau; Peter Hillemanns; Tjoung-Won Park-Simon
Journal:  Ann Pharmacother       Date:  2011-02       Impact factor: 3.154

6.  Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel.

Authors:  C Y Chu; C H Yang; C Y Yang; G H Hsiao; H C Chiu
Journal:  Br J Dermatol       Date:  2000-04       Impact factor: 9.302

7.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

Authors:  Frank Fossella; Jose R Pereira; Joachim von Pawel; Anna Pluzanska; Vera Gorbounova; Eckhard Kaukel; Karin V Mattson; Rodryg Ramlau; Aleksandra Szczesna; Panagiotis Fidias; Michael Millward; Chandra P Belani
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

9.  Skin ulceration potential of paclitaxel in a mouse skin model in vivo.

Authors:  R T Dorr; K Snead; J D Liddil
Journal:  Cancer       Date:  1996-07-01       Impact factor: 6.860

10.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.